CDK4 and breast carcinoma: The development of specific small molecule inhibitors to CDK4/6, kinases that activate both G1/S transition and cross-talk with other oncogenic pathways, demonstrated the expected preclinical effects, particularly in HR+ breast cancer cell line models and exhibited acceptable toxicity in early-phase clinical trials14.